Agenus Announces Resignation of Principal Accounting Officer

Agenus ( (AGEN) ) has shared an update.

On May 12, 2026, Agenus Inc. disclosed that its Senior Director of Financial Reporting and Compliance and Principal Accounting Officer, Austin Charette, had informed the company of his decision to resign. His departure is scheduled to take effect on May 29, 2026, marking a near-term leadership transition in the company’s financial reporting function.

This change in a key accounting leadership role may affect continuity in Agenus’s financial oversight and reporting processes as the company navigates the transition. Stakeholders will be watching how Agenus manages the replacement process and maintains stability in its finance organization during this period.

The most recent analyst rating on (AGEN) stock is a Buy with a $23.00 price target. To see the full list of analyst forecasts on Agenus stock, see the AGEN Stock Forecast page.

Spark’s Take on AGEN Stock

According to Spark, TipRanks’ AI Analyst, AGEN is a Neutral.

The score is held back primarily by weak cash flow and a strained balance sheet (negative equity and reliance on external capital), alongside bearish technical momentum. These are partially offset by the recent swing to reported profitability and a low P/E on the provided data, plus a modest positive impact from reduced legal risk after the class action dismissal.

To see Spark’s full report on AGEN stock, click here.

More about Agenus

Agenus Inc. is a biotechnology company focused on developing immuno-oncology therapies to treat cancer. The company operates in the biopharmaceutical industry, advancing antibody-based treatments and other immune-modulating products aimed at improving patient outcomes in oncology.

Average Trading Volume: 780,623

Technical Sentiment Signal: Sell

Current Market Cap: $149.1M

Learn more about AGEN stock on TipRanks’ Stock Analysis page.